Experimental tissue repair
Preclinical
Tβ4 has preclinical literature. Marketed TB-500 is not a proven clinical equivalent.
Also known as Thymosin beta-4 fragment, Tβ4 fragment (marketed as TB-500)
Marketed research peptide associated with thymosin beta-4 biology. Clinical effectiveness and product identity are not sufficiently established.
TB-500 is a name used in research-chemical markets, generally linked to thymosin beta-4 (Tβ4) or fragments thereof. Endogenous Tβ4 is an actin-binding peptide with a preclinical literature on repair models. Marketed TB-500 is not an FDA-approved drug, and vial contents are not independently verified here.
Thymosin beta-4 is a natural peptide involved in actin regulation. TB-500 is a commercial name, not a licensed drug brand in the FDA sense.
Preclinical repair hypotheses should not be read as proven sports-medicine treatments.
Researchers have studied thymosin beta-4 because it interacts with actin, a protein that helps cells move and keep their shape. TB-500 is sold as if it were that biology in a vial. That leap is not scientifically established for commercial products.
Tβ4 binds G-actin and has been investigated in tissue-injury models. Marketed fragments may not reproduce endogenous Tβ4 pharmacology. Human dosing, exposure, and outcomes are not sufficiently established.
Step 1
Peptide
TB-500 / Tβ4-related fragment (product-dependent)
Step 2
Proposed target
Actin-related cell motility pathways (endogenous Tβ4 biology)
Step 3
Pathway
Experimental repair models
Step 4
Observed research effect
Preclinical Tβ4 literature; TB-500 product effects not established
Tβ4 has preclinical literature. Marketed TB-500 is not a proven clinical equivalent.
Adequate clinical evidence for marketed TB-500 is not sufficiently established.
Tβ4 biology includes actin sequestration and cell-migration hypotheses in experimental systems. Translation to TB-500 products is uncertain.
No sourced study cards have been attached yet. Information not sufficiently established at the study-card level.
Safety information may be incomplete, especially for experimental peptides.
Safety information may be incomplete, especially for experimental peptides. Consult a qualified healthcare professional for personal medical advice.
Long-term safety: Not sufficiently established.
Evidence limitations: Name recognition in sports forums is not clinical evidence.
Administration practices vary by compound and clinical context. Follow approved prescribing information or guidance from a qualified healthcare professional. This page does not provide injection technique, mixing, or personalized dosing instructions.
Discovery
complete
Tβ4 biology; later commercial TB-500 naming.
Preclinical research
in progress
Actin and repair models for Tβ4.
Human studies
not started
Adequate TB-500 clinical package not established here.
Regulatory status
not started
Not approved.
It is marketed that way. Product identity is not verified here, and it is not an approved medicine.
No.
Tissue Research
Experimental pentadecapeptide investigated primarily in preclinical gastrointestinal and tissue-injury models. Human evidence is extremely limited.
View peptide →